Bisphosphonate: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
mNo edit summary |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[medicine]], '''bisphosphonates''' are medications which "contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents."<ref>{{MeSH}}</ref> | In [[medicine]], '''bisphosphonates''' are medications which "contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect [[calcium metabolism]]. They inhibit ectopic calcification and slow down [[bone resorption]] and [[bone turnover]]. [[Technetium]] complexes of diphosphonates have been used successfully as [[bone scanning]] agents."<ref>{{MeSH}}</ref> | ||
Bisphosphonates are used to prevent fractures among patients with [[osteoporosis]] or low bone mass. | Bisphosphonates are used to prevent fractures among patients with [[osteoporosis]] or low bone mass. Other indications include [[glucocorticoid]] Induced Osteoporosis, [[hypogonadal osteoporosis in males]], [[Paget's Disease]] of bone, [[Post-menopausal osteoporosis]], Post-Menopausal Osteoporosis Prevention, Prevention of [[Glucocorticoid-induced osteoporosis]].<ref>{{citation | ||
| publisher = American Society of Hospital Pharmacists & Medscape | |||
| title = Alendronate: Dosage, Usage and Warnings | |||
| url = http://www.medscape.com/druginfo/dosage?drugid=1257&drugname=Alendronate+Oral&monotype=default}}</ref> | |||
Examples of bisphosphonates include [[alendronate]], [[risedronate]], [[etidronate]], [[ibandronate]], [[pamidronate]], and [[zoledronic acid]]. | |||
==Treatment== | |||
Patients should also receive [[Vitamin D]] and [[calcium]]. | |||
==Adverse effects== | ==Adverse effects== | ||
[[Atrial fibrillation]] may be caused by [[zoledronic acid]].<ref name="pmid17476007">{{cite journal |author=Black DM, Delmas PD, Eastell R, ''et al.'' |title=Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1809–22 |year=2007 |month=May |pmid=17476007 |doi=10.1056/NEJMoa067312 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17476007&promo=ONFLNS19 |issn=}}</ref> | [[Atrial fibrillation]] may be caused by [[zoledronic acid]].<ref name="pmid17476007">{{cite journal |author=Black DM, Delmas PD, Eastell R, ''et al.'' |title=Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1809–22 |year=2007 |month=May |pmid=17476007 |doi=10.1056/NEJMoa067312 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17476007&promo=ONFLNS19 |issn=}}</ref> | ||
| Line 15: | Line 19: | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15122554 }} </ref> A systematic review of published cases was reported in 2006.<ref name="pmid16702591">{{cite journal| author=Woo SB, Hellstein JW, Kalmar JR| title=Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. | journal=Ann Intern Med | year= 2006 | volume= 144 | issue= 10 | pages= 753-61 | pmid=16702591 | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15122554 }} </ref> A systematic review of published cases was reported in 2006.<ref name="pmid16702591">{{cite journal| author=Woo SB, Hellstein JW, Kalmar JR| title=Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. | journal=Ann Intern Med | year= 2006 | volume= 144 | issue= 10 | pages= 753-61 | pmid=16702591 | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16702591 }} </ref> In March, 2004. The [[Food and Drug Administration]] asked Novartis to revise the label for Aredia.<ref>[Aredia http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=AREDIA]</ref> | | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=16702591 }} </ref> In March, 2004. The [[Food and Drug Administration]] asked Novartis to revise the label for Aredia.<ref>[Aredia http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=AREDIA]</ref> | ||
==Alternatives== | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 06:01, 19 July 2024
In medicine, bisphosphonates are medications which "contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents."[1]
Bisphosphonates are used to prevent fractures among patients with osteoporosis or low bone mass. Other indications include glucocorticoid Induced Osteoporosis, hypogonadal osteoporosis in males, Paget's Disease of bone, Post-menopausal osteoporosis, Post-Menopausal Osteoporosis Prevention, Prevention of Glucocorticoid-induced osteoporosis.[2]
Examples of bisphosphonates include alendronate, risedronate, etidronate, ibandronate, pamidronate, and zoledronic acid.
Treatment
Patients should also receive Vitamin D and calcium.
Adverse effects
Atrial fibrillation may be caused by zoledronic acid.[3]
Osteonecrosis of the jaw was first reported in September, 2003; however, one publication suggested biphosphonates were causal[4] whereas the other study did not make this assertion as the patients were also taking other medications[5]. The following month, Novartis which is the manufacturer of Zometa, tried to refute the claim.[6] A series of 63 patients were reported in 2004 in which the author asserted that biphosphosphonates were causal.[7] A systematic review of published cases was reported in 2006.[8] In March, 2004. The Food and Drug Administration asked Novartis to revise the label for Aredia.[9]
Alternatives
References
- ↑ Anonymous (2024), Bisphosphonate (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Alendronate: Dosage, Usage and Warnings, American Society of Hospital Pharmacists & Medscape
- ↑ Black DM, Delmas PD, Eastell R, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". N. Engl. J. Med. 356 (18): 1809–22. DOI:10.1056/NEJMoa067312. PMID 17476007. Research Blogging.
- ↑ Marx RE (2003). "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.". J Oral Maxillofac Surg 61 (9): 1115-7. PMID 12966493.
- ↑ Wang J, Goodger NM, Pogrel MA (2003). "Osteonecrosis of the jaws associated with cancer chemotherapy.". J Oral Maxillofac Surg 61 (9): 1104-7. PMID 12966490.
- ↑ Tarassoff P, Csermak K (2003). "Avascular necrosis of the jaws: risk factors in metastatic cancer patients.". J Oral Maxillofac Surg 61 (10): 1238-9. PMID 14586868.
- ↑ Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004). "Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.". J Oral Maxillofac Surg 62 (5): 527-34. PMID 15122554.
- ↑ Woo SB, Hellstein JW, Kalmar JR (2006). "Narrative [corrected review: bisphosphonates and osteonecrosis of the jaws."]. Ann Intern Med 144 (10): 753-61. PMID 16702591.
- ↑ [Aredia http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=AREDIA]